Skip to main content

Table 1 Patients’ characteristics

From: Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

UPN

Diagnosis

Disease status

Light chain isotype

Cytogenetics

ISS stage

Therapy at sampling

Clinical status*

1

MM

Relapse

IgG κ

Normal

III

PDN, Cy

Deceased

2

SMM

Onset

IgG λ

t(4;14)

N.A.

None

Alive/SMM

3

MM

Stable disease

Non secretory

Normal

I

None

Alive/PR

4

SMM

Onset

IgA κ

Normal

N.A.

None

Alive/SMM

5

MM

Partial response

IgG κ

Normal

I

PDN, Thalidomide

Alive/PR

6

MM

Onset

IgG κ

Del(13q); t(4;14)

I

None

Deceased

7

MM

Onset

IgA λ

Normal

III

None

Lost at follow-up

8

MM

Onset

IgG λ

Del(13q)

I

None

Alive/PR

9

MM

Onset

IgD λ

Del(13q)

I

VMPT

Alive/CR

10

MGUS

--

Micromolecular, λ

Normal

N.A.

None

Alive/MGUS

11

MM

Onset

Micromolecular, κ

Normal

I

Prednisone

Alive/Stable disease

12

MGUS

--

IgG κ

Normal

N.A.

None

Alive/MGUS

13

MM

Onset

Micromolecular, κ

Normal

III

Auto-HSCT

Alive/CR

14

MM

Relapse

IgA κ

Del(13q)

I

Prednisone

Alive/PD

15

MM

Onset

NA

Normal

II

None

NA

16

MM

Partial response

IgG λ

Normal

III

PDN

Alive/Stable disease

17

MM

Relapse

IgA λ

Normal

III

PDN

Alive/PR

18

SMM

Onset

IgA κ

Normal

N.A.

None

Alive/progressed to MM

19

MM

Relapse

IgA κ

p53 mutation

II

None

Alive/PR

20

MM

Stable disease

IgG κ

Normal

I

MP

Deceased

21

SMM

Onset

IgG λ

Normal

N.A.

None

Alive/SMM

22

MGUS

--

IgG κ

Normal

N.A.

None

Alive/MGUS

23

MM

Onset

IgG κ

t(11;14);14q32 translocation

I

None

Alive

24

MM

Onset

IgG κ

Del(13q); del(17p)

II

None

Alive

25

MM

Relapse

IgA

Del(13q); t(4:14)

II

None

Alive, relapse

26

MM

Onset

Micromolecular, λ

ND

III

None

Alive/PR

27

MM

Relapse

Non secretory

ND

I

None

Alive/VGPR

28

MM

Relapse

IgA λ

Normal

I

None

Alive/VGPR

29

MM

Onset

IgA κ

Del(13q); del(17p)

III

None

Alive/PD

30

MM

Onset

IgA λ

Del(13q); t(4:14)

I

None

Alive/PR

31

MM

Relapse

IgG κ

ND

I

Prednisone

Alive/PD

32

MM

Relapse

IgG κ

ND

I

None

Alive/PR

  1. Patients’ characteristics. Patients’ demographics, disease features, medical therapies and disease status at sampling are shown. Abbreviations: SMM smoldering multiple myeloma, CR complete remission, PR partial remission, PD progressive disease, VGPR very good partial response, NA not applicable, ND not done, BJ Bence-Jones proteinuria. PDN prednisone, Cy cyclophosphamide, MP melphalan + prednisone, VMPT bortezomib, melphalan, prednisone and thalidomide
  2. *12 months after inclusion in the study.